Chicago, Illinois (December 23, 2021) – Linden Capital Partners (“Linden”), a leading healthcare private equity firm, today announced the closing for its fifth buyout fund, Linden Capital Partners V (“Fund V”). Similar to prior Linden buyout raises, this fundraise was oversubscribed above its hard cap of $3.0 billion of limited partner commitments.
“We are grateful for our investors’ support as we seek to create exceptional companies and deliver attractive returns,” said Tony Davis, Linden’s President and Managing Partner. “As one of the largest and longest-standing dedicated healthcare private equity firms, we believe we’re well-positioned to continue to execute our investment strategy over the course of Fund V.”
Since Linden Capital Partners’ founding in 2004, the firm has focused on middle-market healthcare investments across services, products, and distribution. Linden seeks to create long-term sustainable growth by implementing proprietary value creation programs, emphasizing human capital, and leveraging integrated financial and operating experience. Over the last several years, Linden has strategically built out its team, which has grown to 42 professionals, including a buyout investment team of 20 professionals. In addition to its buyout funds, Linden also manages a non-control, structured capital fund, which closed in June 2021.
“We’re extremely pleased with this outcome, especially in such a crowded fundraising environment,” added Katie Kornel, Linden’s Investor Relations Partner. “With this raise, we continued to diversify our investor base, which now includes investors from over 20 countries. We’re honored to manage capital on behalf of some of the world’s largest and most sophisticated institutions.”
Kirkland & Ellis LLP served as legal advisors, and PJT Park Hill served as placement advisor.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on the healthcare industry. Founded in 2004, Linden is one of the country’s largest dedicated healthcare private equity firms. Linden’s strategy is based upon three elements: (i) healthcare specialization, (ii) integrated private equity and operating expertise, and (iii) its differentiated human capital program. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Since its founding, Linden has invested in over 40 healthcare companies encompassing over 200 total transactions. The firm has raised over $6 billion in limited partner commitments since inception. For more information, please visit www.lindenllc.com.
